Skip to main content

Talk Bio

Search This Blog

Pfizer hunts for new CFO as Denton prepares to leave for consumer goods sector

on June 18, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Pfizer's CFO Dave Denton will step down on August 15, 2026, to pursue a role in the consumer goods industry, prompting the company to launch an internal and external search for a permanent successor.

Cecile Guegan, currently Senior Vice President of Finance for Pfizer's Global Biopharmaceutical Business, has been named interim CFO effective August 16, 2026, while the search for a permanent CFO is underway.

Pfizer emphasizes that Denton's departure is not related to any financial or operational issues or disagreements on accounting or reporting policies, framing it as a voluntary career move.

Sources:

Pfizer CFO Dave Denton to leave company in August - CNBC

Episode 527: Pfizer CFO Dave Denton on Oncology ... - YouTube

Pfizer names interim CFO as Dave Denton departs | PFE 8-K Filing

Pfizer Announces Chief Financial Officer Transition

Pfizer Shares Slip Following CFO Transition Announcement

Pfizer appoints David Denton as chief financial officer and executive ...

Pfizer Launches CFO Search as Denton Plans to Depart in August

Vaccine Makers Pfizer, Moderna Hire New CFOs

Dave Denton - Pfizer

Pfizer (PFE) Announces CFO Resignation and Interim Successor

Pfizer CFO Dave Denton to leave company in August - Investing.com

Pfizer signals big M&A plans with new CFO Denton, the money manager behind the CVS-Aetna merger

Pfizer's Post - LinkedIn

Pfizer Shares Dip 1.5% as CFO Dave Denton Announces Exit

Pfizer Names David M. Denton Chief Financial Officer

Cecile Guegan interim CEO CFO Dave Denton Leadership Pfizer search - EntityNameUse Transition Mutation

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC